Systemic treatment initially with androgen deprivation therapy (ADT) is the standard of care, aiming to reduce androgen receptors and result in tumor shrinkage, including bilateral orchiectomy, AR antagonism (i.e., inhibition of luteinizing hormone-releasing hormone (LHRH) and/or luteinizing hormone), and inhibition of androgen synthesis [4,5]. The gene discussed is AR; the disease is neoplasm.